Logo

Don Hardison

May 04, 2016

HTG Molecular Diagnostics  has appointed Don Hardison to its board of directors. Most recently, Hardison served as president, CEO, and member of the board of directors for Good Start Genetics from April 2010 to March of this year. Prior to his work at Good Start Genetics, he has held a number of executive and senior management positions at various companies, including Laboratory Corporation of America, Exact Sciences, OnTarget, Quest Diagnostics, and SmithKline Beecham.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.